> Shares of Cypress Bioscience soared this morning on positive Phase III data on Milnacipran for fibromyalgia pain. The drug is already approved for depression and researchers noted a significant reduction in pain among volunteers taking the drug. Report
> The FDA has approved Wyeth's Lybrel, a contraceptive that stops a woman's menstrual cycle. Report
> Amgen is offering $4 billion in senior notes. Report
> A successful Phase IIb study of VR004 in erectile dysfunction and new data for VR776 for erectile dysfunction has opened up some "exciting" licensing opportunities, according to the UK's Vectura. The prospect of a licensing deal was raised as the company reviewed its development programs, including plans to release Phase II data on VR040 for Parkinson's in the third quarter. Report
> Sirtris Pharmaceuticals has completed its $60 million IPO as it begins trading today. It priced its shares at $10, in the middle of its expected range. Report
> Australia's Sigma Pharmaceuticals says it will decide on a possible takeover bid for Symbion Health in the next few weeks. Report
> Helicos Biosciences has cut its IPO price range to $10 to $11 per share. Report
> AstraZeneca is culling 300 marketing jobs from its UK operations. Report
> The European Commission has approved Bristol-Myers Squibb's Orencia for rheumatoid arthritis. Release
And Finally…Once thought rare, virgin births are popping up all around the animal kingdom. Article